INTRAVITREAL INFLIXIMAB FOR THE TREATMENT OF SIGHT-THREATENING CHRONIC NONINFECTIOUS UVEITIS

Purpose: Tumor necrosis factor-alpha is known to play an important role in various immune-mediated ocular diseases. Infliximab, a chimeric monoclonal antibody against tumor necrosis factor-alpha, has been used for the treatment of various chronic systemic and ocular inflammatory diseases. The purpose of this study was to evaluate the effect of intravitreal injection of infliximab on the visual acuity and central macular thickness in patients with chronic noninfectious uveitis. Methods: Ten eyes of 7 patients with chronic persistent noninfectious uveitis who were nonresponsive to conventional previous medications during the previous 3 months were included in this study. The patients received intravitreal injection of 1.5 mg/0.15 mL infliximab. Mean best-corrected visual acuity and mean central macular thickness 1 day before and 4 weeks after the injection were evaluated and compared. Results: Mean logarithm of the minimum angle of resolution before and after injection was 1.37 ± 0.43 and 0.67 ± 0.56, respectively, with statistically significant improvement after injection (P = 0.005). The mean central macular thickness before and after injection was 673.20 ± 338.39 μm and 456.40 ± 317.46 μm, respectively, with a significant decrease in the central macular thickness after the injection (P = 0.005). Conclusion: Intravitreal injection of infliximab may improve the visual acuity and decrease the central macular thickness in patients with chronic noninfectious uveitis and significant visual loss and central macular edema.

[1]  H. Hosseini,et al.  Intravitreal Infliximab in Experimental Endotoxin-Induced Uveitis , 2009, European journal of ophthalmology.

[2]  P. Sfikakis,et al.  Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. , 2009, American journal of ophthalmology.

[3]  E. Ebert,et al.  Infliximab and the TNF-alpha system. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[4]  M. Maia,et al.  Therapeutic monoclonal antibodies in ophthalmology , 2009, Progress in Retinal and Eye Research.

[5]  M. Ramazzotti,et al.  A pilot study on ocular safety of intravitreal infliximab in a rabbit model. , 2008, Investigative ophthalmology & visual science.

[6]  D. Gjertson,et al.  TNFα blockade in human diseases: Mechanisms and future directions , 2008 .

[7]  Yue Wang,et al.  Infliximab Therapy for 2 Patients with Vogt-Koyanagi-Harada Syndrome , 2008, Ocular immunology and inflammation.

[8]  D. Gjertson,et al.  TNFα blockade in human diseases : An overview of efficacy and safety , 2008 .

[9]  G. Jaffe,et al.  Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. , 2007, American journal of ophthalmology.

[10]  G. Valesini,et al.  Biological and clinical effects of anti-TNFalpha treatment. , 2007, Autoimmunity reviews.

[11]  L. Sobrin,et al.  Infliximab therapy for the treatment of refractory ocular inflammatory disease. , 2007, Archives of ophthalmology.

[12]  P. Sfikakis,et al.  TUMOR NECROSIS FACTOR ANTAGONISTS: Preliminary Evidence for an Emerging Approach in the Treatment of Ocular Inflammation , 2007, Retina.

[13]  N. Markomichelakis,et al.  Course of Macular Edema in Uveitis under Medical Treatment , 2007, Ocular immunology and inflammation.

[14]  T. Demir,et al.  The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis. , 2006, Indian journal of ophthalmology.

[15]  E. Abboud,et al.  Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease , 2006, International Ophthalmology.

[16]  S. Lightman,et al.  Anti-TNF therapies in the management of acute and chronic uveitis. , 2006, Cytokine.

[17]  P. Manners,et al.  Infliximab for juvenile idiopathic arthritis‐associated uveitis , 2005, Clinical & experimental ophthalmology.

[18]  P. Sfikakis,et al.  Infliximab for chronic cystoid macular edema associated with uveitis. , 2004, American journal of ophthalmology.